SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is gaining traction within the crypto community, with discussions focusing on its cultural significance and potential. Community members are actively sharing links to the Weedcoin website and DEX Screener, while emphasizing the importance of embracing and preserving the "culture." The coin is presented as more than just a cryptocurrency, but rather a movement.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as the community rallies around its positive narrative and long-term vision, emphasizing conviction and community support. Bullish sentiment is fueled by the token's strong community and a belief that it's poised for significant growth, particularly within the Solana ecosystem. Discussions also highlight anticipation for potential listings and the project's alignment with broader crypto trends.

"What's Updog?" is a Community Led token.

UpDog

$UPDOG is trending as the community celebrates its joke-inspired meme-coin status and continued presence on the Solana network. Active discussions revolve around the classic "What's Updog?" joke, with the community emphasizing its commitment and longevity in the crypto space, particularly its listing on Jupiter.

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network is trending as the community anticipates the sunsetting of $PRQ, expecting it to remove arbitrage pressures and allow $REACT to trade more freely.  Enthusiasm is building around potential tier-1 exchange listings and the project's cross-chain smart contract technology, with some community members drawing comparisons to early-stage, high-potential cryptos. Bullish sentiment is fueled by recent integrations and partnerships, as well as a growing number of watchers.

Grayscale Ethereum Trust (ETH) operates as open-end investment company. Its investment objective is for the shares to reflect the value of ETH held by the trust. The company was founded on December 13, 2017 and is headquartered in Stamford, CT.

Grayscale Ethereum Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Ethereum Mini Trust

Grayscale Ethereum Mini Trust ($ETH) is trending amidst fluctuating market conditions, as the community discusses its potential and key support levels. Community members are closely watching for a breakout past all-time highs, fueled by institutional interest and potential rate cuts, while also debating its relationship with other cryptocurrencies and treasury plays. Recent news of large Ethereum purchases, BlackRock's activity, and regulatory developments are adding to the buzz.

Valvoline, Inc. engages in the production, marketing, and supply of engine and automotive maintenance products and services. It operates through the Retail Services segment. The Retail Services segment services the passenger car and light truck quick lube market in the US and Canada with preventive maintenance services done through company operated and independent franchise care stores. The company was founded by John Ellis in 1866 and is headquartered in Lexington, KY.

Valvoline Inc

Valvoline is trending as community members discuss the potential for the stock to test all-time highs, driven by planned store openings and expansion into electric vehicle services. Many see it as a safe, long-term hold with financial AI analysis supporting its health. Bullish sentiment is fueled by significant buy orders and expectations for a positive run in the coming weeks.

$GRIPPY is the sticky meme frog of Base — goofy, wholesome, and powered by pure meme energy.   Inspired by Furie-style chaos and community culture, Grippy isn’t just another frog, he’s a sticky symbol of resilience, humor, and diamond-handed holding. Built with zero taxes, a renounced contract, and liquidity locked, $GRIPPY launched as a true fair-play meme coin for the people.  The project thrives on organic growth, viral campaigns, and community-driven governance. With staking pools, a Grippy Dashboard, and merch/NFT drops in the roadmap, $GRIPPY is here to stick as Base’s No. 1 meme.

GRIPPY

Grippy is trending as community members discuss its potential, low market cap, and availability on Coinbase. Speculation around upcoming listings on Bitmart and Pionex, along with a potential partnership, is fueling excitement. Comparisons to other meme coins like Doge and Shiba Inu are also circulating.

Hydrex is the MetaDEX & Liquidity Infrastructure purpose-built for Base. By combining automated strategies, liquid-backed tokenomics, and Base's powerful distribution channels, Hydrex removes the barriers to yield. It's designed as a coordination system where weekly community governance directs HYDX emissions & protocol revenue. Value flows to where liquidity and volume are most productive, based on protocol alignment.

Hydrex

Hydrex ($HYDX) is trending as a potential competitor to $AERO, with community members highlighting its recent launch on Base as a DUNA and locked tokenomics. Discussion centers on its potential for significant gains, driven by social media activity and comparisons to a larger market cap project, while some investors are drawn to its long-term potential.

Baby Doge Coin is a meme cryptocurrency designed to be deflationary and more scarce over time. All holders of Baby Doge will earn more baby doge that is automatically sent to your wallet by simply holding Baby Doge coins in your wallet. Watch the amount of baby doge grow in your wallet as baby doge coin holders automatically receive a 5% fee from every on chain transaction that happens on the Baby Doge ecosystem. The community receives more baby doge coins from the fees generated each transaction.

Baby Doge Coin

Baby Doge Coin is gaining traction as the community anticipates potential listings on major exchanges like Coinbase and Crypto.com, speculating this could trigger a significant price surge. Fueling the excitement is the coin's impressive trading volume and the ongoing bullish sentiment surrounding meme coins.

$LEASH is the second token in the Shiba Inu Ecosystem. It was originally envisioned to be a rebase token tied to the price of DogeCoin. Later, it was decided that Leash would turn off the rebase function (the keys to allow rebase were burnt to ensure this) and continue as a simple ERC-20 Token.   Though simple, the fact that LEASH’s tokenomics are the polar opposite of SHIB makes it even more intriguing.   SHIB was made to have an enormous supply of (1 quadrillion tokens) with half locked away, whereas the supply of Leash is only 107,647 minted tokens.

Doge Killer

LEASH is trending as community members express frustration and disappointment, with some labeling the project a scam or rug pull. The discussions revolve around the perceived failure of the token, significant price drops, and concerns about funds being extracted from the ecosystem.  However, some community members remain optimistic and highlight the token's limited supply.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Faruqi & Faruqi Reminds Biohaven Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 12, 2025 - BHVN

Faruqi & Faruqi Reminds Biohaven Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 12, 2025 - BHVN Faruqi & Faruqi Reminds Biohaven Investors of the Pending...

Class Action Filed Against Biohaven Ltd. (BHVN) Seeking Recovery for Investors - Contact Levi & Korsinsky

Class Action Filed Against Biohaven Ltd. (BHVN) Seeking Recovery for Investors - Contact Levi & Korsinsky Class Action Filed Against Biohaven Ltd. (BHVN) Seeking Recovery for Investors - Contact Levi...

Biogen shares slipped on Monday after the company said it expects to take a $46 million charge in the second quarter related to R&amp;D deals and milestone payments.&nbsp;The expense is set to shave&nbsp;off about $0.26 off its per-share earnings, both on a GAAP and adjusted basis.The update adds to investor caution following the FDA’s recent signal report published on June 30, which named Biogen’s Alzheimer’s treatment Leqembi as one of several drugs flagged for potential post-marketing safety concerns.&nbsp;The report, compiled from the FDA’s FAERS database, represents a push for increased transparency around adverse event reporting.Analysts at RBC Capital said they do not anticipate major regulatory fallout, noting that the data was already publicly available and the risks broadly acknowledged.&nbsp;However, they said the FDA’s move could still create some sentiment overhang for Biogen and other named firms, including Sarepta, Alkermes, Biohaven, Xenon, and Argenx.<a href="https://stocktwits.com/symbol/BIIB">Biogen’s</a> newly itemized R&amp;D charges follow its Q1 decision to present such costs as a separate line item on its income statement.&nbsp;The company stated that these typically include expenses from licensing deals and asset acquisitions, which are accounted for as in-process research and development.Meanwhile, Biogen is advancing its drug pipeline, beginning a Phase 3 study with felzartamab, which can treat a kidney condition known as primary membranous nephropathy.The trial, dubbed Prominent, began dosing patients late last month and will enroll about 180 adults.On Stocktwits, retail sentiment for Biogen was ‘bullish’ amid ‘low’ message volume.Biogen’s stock has declined 13.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the logo of Biogen is seen on a smartphone with the FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)  

Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit

The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share.

Equity

Biohaven Pharma stock tumbles after withdrawal of Dazluma application in EU

Investing.com -- Biohaven Pharma (NYSE: BHVN) shares fell sharply by as much as 21% as the company withdrew its marketing authorization application for Dazluma in Europe, intended to treat spinocerebellar ataxia genotype 3 (SCA3). The stock's downturn followed a brief trading halt due to volatility.

Biotech stocks jump as Makary outlines FDA vision, RBC comments

Investing.com -- Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers. In his first major interview since taking office, Makary emphasized pragmatic reforms, faster drug approvals, and modernized use of real-world data across the agency.

Deutsche Bank initiates coverage of biopharma stocks, sees 'modest recovery'

Investing.com -- Deutsche Bank initiated coverage on 11 U.S. biopharma stocks in a note Tuesday, assigning Buy ratings to eight companies and Hold ratings to three. 

Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia

Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia Biohaven Announces FDA Acceptance and Priority Review of...

Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation P

Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective...

Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire NEW HAVEN, Conn., Jan. 7, 2025 NEW HAVEN...

Shares of Biohaven (BHVN) gained in morning trade on Tuesday after the company’s director John W. Childs acquired shares worth $1.04 million on Monday.According <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/1935979/000193597924000088/xslF345X05/wk-form4_1735646406.xml">to</a> Biohaven’s U.S. Securities and Exchange Commission (SEC) filing, Childs acquired 29,000 shares of the company for the benefit of John W. Childs Revocable Trust, at an average price of $35.9446 apiece, over 3% lower than the current market price of $37.07.Biohaven is a Connecticut-based biopharmaceutical company that focuses on the discovery and development of drugs across therapeutic areas like neuroscience, immunology, and oncology.Earlier this month, the company reported that it achieved essential milestones in the trial of its experimental drug BHV-1300, intended for use in treating a kidney disease. Biohaven also has other trials underway to treat autoimmune diseases.Analysts at RBC Capital raised their price target for the Biohaven stock to $61 from $58 while maintaining an ‘Outperform’ rating, according to TheFly.However, in November, the company’s spinal muscular atrophy (SMA) trial misfired after it failed to achieve its primary endpoint.Reacting to the news of Childs acquiring company shares, Biohaven stock gained over 4% in morning trade on Tuesday, before paring some of the gains.Retail sentiment on Stocktwits entered the ‘bullish’ territory (58/100), with message volume picking up, too.<figure class="image"><img style="aspect-ratio:649/147;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_31_213107_8d3615ce5c.jpg" alt="BHVN stock sentiment" width="649" height="147"><figcaption>BHVN sentiment and message volume December 31, 2024, as of 11:30 am ET | Source: Stocktwits</figcaption></figure>Overall, though, Biohaven’s shares are down nearly 18.5% over the past month, and 13% year-to-date.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/axsome-therapeutics-stock-tumbles-as-alzheimer-studies-reveal-mixed-results/cJOiJFyRki">Axsome Therapeutics Stock Tumbles As Alzheimer's Studies Reveal Mixed Results: Retail Sentiment Remains Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

An employee pipettes in a laboratory of a biopharmaceutical company | Photo by Bernd Weißbrod/picture alliance via Getty Images

Biohaven Stock Surges After Director Acquires Shares Worth Over $1M: Retail Sentiment Turns Bullish

Earlier this month, Biohaven reported achieving important milestones in the trial of its experimental drug BHV-1300, which is intended for use in the treatment of kidney disease.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$1.88	--	--	N/A
Q2 '25	-$1.90	-$1.94	-1.99%	MISSED
Q1 '25	-$1.70	-$2.17	-27.62%	MISSED
Q4 '24	-$1.57	-$1.85	-17.47%	MISSED
Q3 '24	-$1.70	-$1.70	0.09%	BEAT

BHVN
Biohaven Pharmaceutical Holding Company Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest BHVN News

BHVN Biohaven Pharmaceutical Holding Company Ltd